Indian generic-drug makers once bedeviled Big Pharma; now they may be its best hope for success.
By Jason Overdorf
March 5, 2007 issue - India used to be big pharma's worst nightmare. Loose patent laws and a glut of talented scientists made that country the world capital for generics. As quickly as companies like GlaxoSmithKline, Merck, Novatis, Pfizer and others could develop innovative new drugs, nimble Indian companies could copy them—and sell them for a fraction of the price. The practice led to a tangle of litigation. But now, the legal battles are giving way to new partnerships. Click to read the rest.